Melanoma & Skin Cancer | Specialty

The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

Immunotherapy Combinations Reign Supreme in Upfront Melanoma Management

February 28th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses long-term data that inform the sequencing of immunotherapy and targeted therapies for frontline melanoma.

Dr Patel on the Potential for Adjuvant Immunotherapy in CSCC

February 24th 2025

Sapna Patel, MD, discusses the potential for adjuvant immunotherapy in patients with high-risk cutaneous squamous cell carcinoma.

The OncFive: Top Oncology Articles for the Week of 2/16

February 22nd 2025

FDA grants priority review to zongertinib in HER2-mutant NSCLC and dordaviprone for recurrent H3K27M+ diffuse glioma, and more from OncLive this week.

Updated NCCN Guidelines Recommend HEPZATO KIT for Hepatic-Dominant Uveal Melanoma

February 19th 2025

The NCCN Guidelines for metastatic uveal melanoma now recommend HEPZATO KIT as a Category 2A treatment option for patients with hepatic-dominant disease.

Observation Is a Reasonable Alternative to Adjuvant PD-1 Blockade in Stage IIB/IIIC Melanoma

February 18th 2025

Tara C. Mitchell, MD, discusses considerations and lingering questions regarding pre- and post-operative management strategies in stage IIB/IIIC melanoma.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Nivolumab Plus Relatlimab Fails to Improve RFS in Resected Stage III/IV Melanoma

February 14th 2025

Nivolumab plus relatlimab did not improve recurrence-free survival vs nivolumab in resected stage III/IV melanoma.

Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma

February 12th 2025

Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.

NCCN Updates ctDNA Stance in Colon, Rectal, and MCC Guidelines

February 12th 2025

The NCCN guidelines have been updated to specify the standing of ctDNA as a biomarker in colon and rectal cancer, as well as in MCC.

Dr Hamid on the Potential for Cancer Vaccines in Melanoma

February 12th 2025

Omid Hamid, MD, provides insight on the potential role of cancer vaccines in melanoma.

Dr Orloff on Treatment Strategies for Rapidly Progressing Uveal Melanoma

February 11th 2025

Marlana M. Orloff, MD, discusses optimal therapeutic approaches for patients with uveal melanoma that is rapidly progressing.

Dr Faries on Emerging CAR T-Cell and TCR Cell Therapies in Melanoma

February 11th 2025

Mark Faries, MD, discusses how CAR T-cell and TCR cell therapies compare with TIL approaches in melanoma.

Fox Chase Cancer Center Researchers Review Guidelines for Therapies Given to Melanoma Patients Before and After Initial Treatment

February 11th 2025

A team of colleagues at Fox Chase Cancer Center recently published an updated review of guidelines governing the use of neoadjuvant and adjuvant therapy for patients with melanoma.

Dr Akkooi on Pathologic Review Discrepancies and Overtreatment Risks in Metastatic Melanoma

January 27th 2025

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

The OncFive: Top Oncology Articles for the Week of 1/19

January 25th 2025

Treosulfan wins FDA approval for allHCT conditioning in AML and MDS, RP1/nivolumab gets priority review in melanoma, and more this week from OncLive.

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

January 21st 2025

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma

January 14th 2025

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Phase 3 Study of Ameluz-PDT in Superficial Basal Cell Carcinoma Reaches 1-Year Follow-Up to Support FDA sNDA Submission

January 8th 2025

The phase 3 ALA-BCC-CT013 study of Ameluz and RhodoLED PDT in sBCC had its last enrolled patient complete a 1-year follow-up visit.